Dr. Karim Dabbagh, Director of Pharmacology at Roche to present at GTCbio's 3rd Protein Kinase in Drug Discovery Conference on May 5-6, 2008 in San Diego, CA
Dr. Karim Dabbagh the Director of Pharmacology at Hoffmann-La Roche will present at GTCbio's 3rd Protein Kinase in Drug Discovery Conference on May 5-6, 2008 in San Diego, CA.


    /Biotechnology News Articles/ - MONROVIA, CA, March 30, 2008 - Dr. Dabbagh¡¦s presentation will cover P38 MAP Kinases and the important roles they play in inflammatory responses. Since P38 MAP Kinases are involved in the generation, as well as the signaling pathways of pro-inflammatory cytokines such as TNF-ƒÑ and IL-1ƒÒ, therapeutic targeting of P38 MAP kinase has been an area of intense pre-clinical and clinical research. Dr. Dabbagh¡¦s presentation will provide preclinical data for P38 inhibitors, the selectivity profile of these inhibitors as well as the safety and efficacy of the P38 inhibitors. The clinical applications of these inhibitors will also be discussed.

GTCbio¡¦s 3rd Protein Kinase in Drug Discovery Conference will take place on May 5-6, 2008 in San Diego, CA and will cover Kinase Drug Design, Kinase Targets and Inhibitors in CNS Disorders, Oncology, and Inflammatory Disorders, as well as New Technologies in Screening and Identifying Targets and Inhibitors.

The conference also features presentations from other leading organizations such as Johnson & Johnson, Roche, Pfizer, Merck, GlaxoSmithKline, Salk Institute, AstraZeneca, Methylgene, UCSD, and many more. The full agenda is available online at www.gtcbio.com.

For more information including a detailed agenda, exhibitor opportunities and registration information visit http://gtcbio.com/userAgenda.aspx?id=121

Further Related Resources:


Press Release Contact Information:

Rania Hafez
GTCbio
Marketing Director
434 W. Foothill Blvd.
Monrovia, CA
USA 91106
Voice: 626-256-6405
Fax: 626-256-6460
Website: Visit Our Website